DLH to Present at the Canaccord Genuity Conference on August 7

ATLANTA, July 22, 2019 /PRNewswire/ — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of innovative healthcare services and solutions to federal agencies, today announced that it will participate in the Canaccord Genuity 39th Annual Growth Conference on August 7, 2019 in Boston, where management will provide an overview of the Company’s operations and outlook. Institutional investors are welcome to participate in one-on-one meetings throughout the day, and a live audio webcast of the Company’s discussion will be available on the DLH website.

About DLH
DLH (NASDAQ:DLHC) serves federal government clients throughout the United States and abroad delivering technology enabled solutions in key health and human services programs. The Company’s core competencies and consulting services include assessment and compliance monitoring, program management, health IT systems integration, data analytics, medical logistics, and pharmacy solutions. DLH has over 1,600 employees serving numerous government agencies. For more information, visit the corporate website at www.dlhcorp.com

DLH Investor Relations
Contact: Chris Witty
Phone:  646-438-9385
Email:  cwitty@darrowir.com

 

View original content:http://www.prnewswire.com/news-releases/dlh-to-present-at-the-canaccord-genuity-conference-on-august-7-300887570.html

SOURCE DLH Holdings Corp.

Staff

Recent Posts

Orange Auto Insurance, Inc., Subsidiary of HPN Holdings, Inc. Announces Reinsurance Partnership

Chicago, Illinois--(Newsfile Corp. - February 5, 2026) - HPN Holdings, Inc. (OTCID: KICK) ("HPN" or…

13 minutes ago

Sacred Connection Launches Comprehensive Educational Guide to Traditional Rapé Medicine

In the newly-released educational guide What Is Rapé?, Sacred Connection covers essential topics around Rapé…

2 hours ago

Endomimetics Announces Strategic Restructuring into IP Foundry to Accelerate Bionanomatrix(TM) Clinical Applications

Accelerating platform-driven clinical innovation across vascular, neurovascular, and cardiovascular applications through a centralized Bionanomatrix™ IP…

2 hours ago

Tenon Medical, Inc. Sets Date for Fourth Quarter and Full Year 2025 Earnings, Reaffirms Expected Revenues

Fourth Quarter 2025 Revenue of $1.45 to $1.48 Million, representing growth of ~90% year over…

2 hours ago

Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging

Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA…

2 hours ago